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Summary. In the Sahel, most malaria deaths occur among children 1–4 years old during a short transmission season. A trial of
seasonal intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) and a single dose of artesunate (AS)
showed an 86% reduction in the incidence of malaria in Senegal but this may not be the optimum regimen. We compared this
regimen with three alternatives. Methods. 2102 children aged 6–59 months received either one dose of SP plus one dose of
AS (SP+1AS) (the previous regimen), one dose of SP plus 3 daily doses of AS (SP+3AS), one dose of SP plus three daily doses of
amodiaquine (AQ) (SP+3AQ) or 3 daily doses of AQ and AS (3AQ+3AS). Treatments were given once a month on three occasions
during the malaria transmission season. The primary end point was incidence of clinical malaria. Secondary end-points were
incidence of adverse events, mean haemoglobin concentration and prevalence of parasites carrying markers of resistance to
SP. Findings. The incidence of malaria, and the prevalence of parasitaemia at the end of the transmission season, were lowest
in the group that received SP+3AQ: 10% of children in the group that received SP+1AS had malaria, compared to 9% in the
SP+3AS group (hazard ratio HR 0.90, 95%CI 0.60, 1.36); 11% in the 3AQ+3AS group, HR 1.1 (0.76–1.7); and 5% in the SP+3AQ
group, HR 0.50 (0.30–0.81). Mutations associated with resistance to SP were present in almost all parasites detected at the end
of the transmission season, but the prevalence of Plasmodium falciparum was very low in the SP+3AQ group. Conclusions.
Monthly treatment with SP+3AQ is a highly effective regimen for seasonal IPT. Choice of this regimen would minimise the
spread of drug resistance and allow artemisinins to be reserved for the treatment of acute clinical malaria. Trial Registration.
Clinicaltrials.gov NCT00132548
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INTRODUCTION
In Sub-Saharan Africa, malaria remains the most common cause
of morbidity and mortality and is still estimated to cause one
million deaths a year, primarily in young children [1]. Insecticide-
treated bednets (ITNs) can reduce mortality and morbidity from
malaria substantially [2] but they are only partially effective and
achieving high levels of coverage with ITNs has proved difficult.
Other preventive strategies are needed.
Administration of antimalarial chemoprophylaxis to the whole
paediatric population can reduce malaria morbidity and all-causes
mortality substantially [3] but this approach to malaria control has
not been adopted widely because of concerns over the enhance-
ment of drug resistance, impairment of naturally acquired
immunity and difficulties in implementation. Intermittent preven-
tive treatment (IPT), the administration of an antimalarial drug or
drug combination in curative doses at specific time points (for
example antenatal clinic visits or visits for routine immunisation)
offers a potential way of achieving some of the gains provided by
chemoprophylaxis whilst limiting some of its potential drawbacks
[4]. Drugs used for IPT must be very safe as well as effective.
Several studies have shown that IPT given with routine
immunisation during the first year of life is effective in reducing
the incidence of clinical malaria and of anaemia [5–9]. In
Tanzania, approximately 50% protection against clinical attacks
of malaria and anaemia was achieved during the first year of life
using sulfadoxine-pyrimethamine (SP) and this protection was
sustained during the following year in the absence of any further
drug administration [5,6]. A second study undertaken in Tanzania
in which amodiaquine (AQ) was given routinely at growth
monitoring visits achieved similar results [7].
However, more recent studies of IPT with SP conducted in
Ghana and Mozambique have given less marked reductions in the
incidence of malaria or anaemia and no persistence of protection
beyond the period of drug administration [8,9]. Further trials of
IPT in infants using alternative drugs to SP are under way in
Kenya and Tanzania under the auspices of the IPTi consortium
[10]. Sufficient data should have been collected within the next
year to determine whether IPT in infants is sufficiently effective to
warrant introduction into the routine expanded programme of
immunisation (EPI).
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seasonal, the main burden of malaria is not in infants but in older
children [11,12] and IPT in infants would not be expected to have a
major impact on the overall burden of malaria in children, unless
protection persists beyond the period of drug administration as
observed in Tanzania [6]. Thus, we and others have explored the
feasibility of using the IPT approach to prevent malaria in older
children [13,14]. In Mali, administration of two doses of SP to
children under fiveyears of age during the malaria season resulted in
a 40% reduction in clinical attacks of malaria [13]. In 2002, children
aged 3–59 months resident in Niakhar, a typical Sudano-Sahelian
area of rural Senegal where malaria transmission is seasonal, were
given a single dose of SP plus one dose of artesunate on three
occasions at monthly intervals during the peak malaria transmission
season. This resulted in an 86% reduction in clinical attacks of
malaria in children without any rebound in the incidence of malaria
during the following year [14]. At the end of the malaria
transmission season, the proportion of malaria parasites carrying
molecular markers for resistance to pyrimethamine and sulfadoxine
was increased in children who had received IPT but the number of
children carrying resistant parasites was less than in the control
group because fewer children had parasitaemia. This increase was
seen despite the fact that children had received an artemisinin-based
combination therapy (ACT). Because of these findings we have
investigated whether other drug regimens might be equally effective
in preventing malaria but more effective in preventing the
emergence of resistant parasites. The regimens were chosen for
evaluation for the following reasons. A combination of two drugs, as
opposed to monotherapy, was used to reduce the risk of the
emergence of resistant parasites. Amodiaquine was chosen as a
component of two of the combinations as this drug is still effective in
Senegal and is moderately long lasting. Treatment trials have shown
that SP combined with three daily doses of amodiaquine is more
effective at preventing 28-day post-treatment relapses or recrudes-
cence than SP combined with artesunate [15] and an important
objective for this trial was to determine whether this would also be
the case for IPT. A one-day regimen of SP plus artesunate was
included as a comparator as this was the schedule used in a previous
IPT trial in Senegal.
MATERIALS AND METHODS
Study area
The study was carried out in Niakhar, a rural district in central
Senegal with 33,000 inhabitants that has for several decades been a
regional observatory for population and health studies [16]. In this
area, rains are concentrated over a three-month period from July to
the beginning of October. Malaria transmission, almost exclusively
by Anopheles arabiensis (A. gambiae s.l.),i ss t r i c t l ys e a s o n a la n d
concentrated in September and October. The parasite rate in
children is usually less than 50% for most of the year but can reach
figures as high as 80% at the end of the rainy season [17]. P. falciparum
is the dominant species. Eighty per cent of malaria deaths occur
among children 0–4 years of age. From 1988 to 1991, the average
malaria mortality rate was 5.4 per thousand per year among children
between 0 and 4 years of age. The emergence of chloroquine
resistance in 1992 [18] was associated with a dramatic increase in
malariamortality,whichaveraged12.4perthousandperyearamong
children under 5 years of age during the period 1992–1995 [19].
Study design
An open label trial was conducted which compared four treatment
regimens: one dose of SP plus one dose of AS (SP+1AS); one dose
of SP plus AS given for three days (SP+3AS); one dose of SP plus
AQ given for three days (SP+3AQ); AQ plus AS both given for
three days (3AQ+3AS). These regimens were chosen for
evaluation because resistance of P. falciparum to SP and AQ is
known to be only modest in the study region and because the use
of combination therapy should reduce the risk of the emergence of
resistant parasites. Eligible participants were allocated to receive
one of the study combinations in early September, early October
and early November 2004.
Enrolment, treatment allocation and drug
distribution
Community meetings were held inthe study area to explainthe aims
and procedures of the study. Information about the trial was
provided in local languages (Serer and Wolof). Oral consent was
sought from a parent or guardian. Fourteen villages were chosen for
logistic convenience and a list of 2102 children living in these villages
and who would be aged between 6 and 59 months at the time of the
first treatment in September was obtained from the Niakhar
demographic surveillance database. These children were invited to
be screened for participation in the trial between July and August
2004. 5 refused to participate, leaving 2097 children who had
parental consent to participate and were enrolled. They were
systematicallyallocatedintheorderinwhichtheyhad beenscreened
in sequence in blocks of four to receive SP+1AS, SP+3AS,
3AQ3+3AS, or SP+3AQ. The children were issued with an ID
cardto facilitate identification at subsequent contacts at home or ina
health centre. When eligibility was checked again on the day of first
treatment in September, 68 children had left the study area, 6 had
died, and 3 were excluded because of illness (2 with acute respiratory
illness and one with chronic illness), leaving 2020 children in the
study. None had a history of allergy to the study drugs.
Study drugs for the three treatment course were placed in
envelopes bearing the child’s ID number. Dosing was according to
weight in two weight groups, ,12 kg and .=12 kg. The dosage of
SP(tabletsof500 mgsulfadoxineand25 mgpyrimethamine)wasK
tablet (,12 kg) or 1 tablet (.=12 kg), dosage of AS (50 mg tablets)
was 1 tablet per dose (,12 kg) or 1.25 tablets (.=12kg), and
dosage of AQ (200 mg tablets), L tablet for children ,12 kg and
1.25 tablets for children .=12 kg. Treatment allocation, packag-
ing, and drug administration were done by staff that played no part
in evaluation of study subjects. The trial was not blinded; as
amodiaquine tablets were yellow parents of children in this group
would have been aware of their treatment allocation; but field staff
involved in evaluation of study subjects, and laboratory staff, were
unaware of a child’s treatment group.
Children were given the first dose of treatment at the health
centre. Subsequent doses were given at home by study staff. For
young children, tablets were crushed and mixed with water prior
to administration. Participants were observed for 15 minutes after
drug administration; if the child vomited the dose was repeated.
Before administration of the first dose, children were examined
and any child who had malaria, defined as fever (temperature by
auricular thermometer .=38uC) or a history of fever or vomiting
within the last 24 hours together with parasitaemia at any density
was not given the IPT treatment that month but was treated with
artemether/lumefantrine (Co-ArtemH).
Patient follow-up, assessment procedures and
clinical management
Participants were visited at home each week over three months
from September to December to record episodes of malaria. At
each visit, axillary temperature was measured and a blood film
made if the child was febrile (.=38uC), or had a history of fever
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slide positive were treated with Coartem over three days. To
ensure detection and prompt treatment of malaria at other times,
parents were encouraged to bring their child to the health centre if
the child was ill. Each parent was given a consultation ticket which
entitled their child to free consultation at the nearest health centre
where physical and parasitological examinations were done
promptly. Children who were treated for malaria were revisited
at least once a day until the third day after treatment to monitor
the child’s recovery. An experienced supervisor checked the
performance of study field-workers by re-visiting in the afternoon
selected participants who had been seen in the morning, to check
for malaria symptoms and the accuracy of data recording.
At the time of the first drug administration (September 2004)
and one month after the third and last drug administration
(December 2004), a finger-prick blood sample was taken from
each child for measurement of haemoglobin concentration,
detection of parasitaemia and for parasite genotyping. Children
who were anaemic (Hb,9 g/dL) at the September survey were
given iron supplementation (children with Hb,9 g/dL were given
one tablet of iron per day for four weeks, children with Hb,7g /
dL were given, in addition, multivitamins and mebendazole for
3 days, according to national guidelines).
Laboratory methods
At the time of the cross-sectional surveys in September and
December, filter paper blood samples were collected and stored for
analysis of molecular markers for resistance. Parasite densities
were estimated in thick blood films, assuming an average white
blood cell count of 8000 per ml. All slides were double read; for
acute cases, to permit prompt treatment, treatment was decided on
the basis of the first reading. Haemoglobin (Hb) concentration was
measured in a HemoCue MachineH. DNA was extracted from
filter papers obtained from parasite positive children using the
chelex technique [21]. Mutations in the pfdhfr and the pfdhps genes
were identified using sequence specific oligo-nucleotide probing
(SSOP) following a method adapted from that of Pearce et al. [22].
Assessments of adverse events
Adverse events were defined as any signs or symptoms which first
appeared, or increased in severity, within seven days of drug
administration. Any serious adverse events such as a death or
admission to hospital was thoroughly investigated and reported
within 24 hours to the Data Safety and Monitoring Board (DSMB)
established to support the trial. To determine the incidence of minor
adverse eventsfollowing drugadministrationallchildrenwerevisited
at home seven days after each round of drug administration and an
adverse events questionnaire completed. The medical team followed
up participants with adverseexperiences until the event was cured or
had stabilised. Parents were also strongly advised to inform project
field staff or to go to the nearest health centre if their child became ill
following drug administration.
Statistical analysis
The primary study endpoint was the incidence of the first or only
episode of malaria, defined as a parasitaemia of 3000/mL or more
together with fever (temperature measured by auricular thermom-
eter $38.0uC) or a history of fever or vomiting in the previous
24 hours. This definition has been shown in nearby Ndiop to have
optimum sensitivity and specificity for diagnosis of clinical malaria
in children under active surveillance (Trape JF and C Rogier,
unpublished). Secondary endpoints were the incidence of adverse
events, the mean Hb concentration, the prevalence of asexual
parasitaemia, and the prevalence of P.falciparum genotypes
associated with resistance to sulfadoxine and to pyrimethamine,
recorded in the cross-sectional survey in December.
Sample size was calculated for comparison of each treatment
group to the group who received SP+1AS, the regimen used in the
trial conducted previously in
Niakhar [14], firstly to establish non-inferiority with respect to
malaria incidence (we assumed an expected cumulative incidence
of malaria of 7% in all groups). We chose a non-inferiority margin
of 5%, and determined the sample size for 90% power and 95%
confidence, allowing for 10% loss to follow-up. Secondly, the study
was designed to have adequate power to detect a reduction in the
overall prevalence of drug-resistant parasite genotypes, assumed to
be about 13% (based on a parasite prevalence of 14% in the
SP+1AS group, 95% of which would be carrying the triple dhfr
mutation associated with resistance to pyrimethamine). Five
hundred and twenty subjects were required for each group.
The primary analysis includes all individuals who were allocated
to treatment provided that they received at least one follow-up visit,
regardless of the number of treatments received. Data have been
analysed according to the treatment group to which a child was
allocated (intention to treat). The analysis plan, finalised and
approved by the DSMB before the treatment code was broken,
specified that the primary analysis should include adjustment for the
covariates age and bednet use. When the data were reviewed,
geographicalarea was found to be strongly associated with the riskof
malaria and was included as a covariate. For analysis, villages were
grouped into two areas, one with a low and one with a high malaria
risk. To determine non-inferiority within the specified 5% margin,
each treatment group was compared to the SP+1AS group using the
95% confidence interval for the difference in malaria risk. When the
95% interval excludes 25% but also lies above zero, a 2-sided P-
valueforthe test of superioritywascalculated.In additionthe hazard
ratio was estimated using Cox’s regression, with observations for
children who were lost to follow up (or died) being censored on the
date they were last seen (or the date of death). In the primary
analysis, only cases with parasitaemia $3000/ml were included; this
is a more specific case definition but the analysis does not take
account of the effects of drug treatment in malaria cases with
densities below this cut-off. Therefore in a secondary analysis, all
treated cases (with parasitaemia at any density) were included.
Differences inmean Hb concentrations between treatment groups in
December were estimated using analysis of covariance, adjusting for
the Hb measurement at enrolment. Incidence of adverse events in
each treatment group was compared using the chi-squared test. All
analyseswere done with STATAsoftware version8(CollegeStation,
TX, USA).
Ethics
In view of the high level of protection against malaria obtained in a
previous trial in the study area using SP+one dose of AS it was not
considered justifiable to include a placebo group in the study. The
study was approved by the ethics review boards of the Senegalese
Ministry of Health and the London School of Hygiene & Tropical
Medicine. The trial was monitored by a DSMB and an
independent trial monitor.
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
RESULTS
Two thousand one hundred and two children aged 6–59 months
were screened and allocated to receive monthly IPT with SP+1AS,
Malaria Preventive Treatment
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children (96%) who were enrolled, treated and followed up for at
least one visit were included in the primary analysis. Surveillance
began on September 6
th 2004, the first IPT treatments were given
in the period 6
th–16
th September 2004, and follow-up ended on
November 28
th 2004. Of these 2020 children, four children died
and a further 83 were lost to follow up before the end of the
surveillance period (Figure 1). Among the 2020 included in the
analysis, 1 child in the SP+1AS group received 2 treatments of
SP+3AQ and missed their third treatment; 18 children (8 in the
SP+1ASgroup, 4 in the SP+3AS group, 4 in the 3AQ+3AS group
and 2 in the SP+3AQgroup) received the wrong treatment on one
or more occasions. Twenty-nine children received no IPT doses
and 1503 (74%) received all 3 treatments. Vomitting of the study
medication was more common in the groups receiving amodia-
quine. The percentage of children that vomitted the first dose of
the treatment round was 0.73% in the SP+1AS group (10
occasions out of 1362), 0.74% (10/1353) in the SP+3AS
group,2.3% (31/1357) in the AQ/AS group and 4.1% (58/
1414) in the SP+3AQ group.
On entry into the trial, the four study groups were well matched
for variables such as age, residence, bednet use and prevalence of
P. falciparum asexual stage parasitaemia (Table 1). At enrolment,
45% of children (883/1974 tested) had a Hb concentration,9g /
dl and received iron supplementation; the proportion who
received supplementation was similar in each treatment group
(Table 1). Use of bednets was limited, 18% (359/1968) slept under
an intact or impregnated bednet.
Malaria incidence
The overall incidence of clinical attacks of malaria in study
children was 9.1% (171/2020). Three children had two malaria
episodes separated by a period of more than 28 days, two children
in the 3AQ+3AS group and one child in the SP+3AS group. No
child had more than two episodes. In addition, there were 7
children who had second episodes within 28 days of the primary
malaria attack (two in the SP+1AS group, two in the SP+3AS
group, two in the 3AQ+3AS group, and one in the SP+3AQ
group) . Incidence by treatment group is shown in Table 2. The
distribution of malaria episodes over time is shown in Figure 2.
Cumulative incidence of malaria was similar in the three
treatment groups that included artesunate in both the intention to
treat and per protocol analyses (i.e. analysis restricted to include
only children who received three treatments; data not shown). The
incidence of malaria in the SP+3AQ group (4.9%) was lower than
in the group that received SP+1AS, with a 95% confidence
interval for the risk difference that excludes zero. The hazard ratio
was 0.50, (95%CI 0.30–0.81), P=0.006. Malaria incidence was
lower in children under 2 yrs than in children 2–5 yrs of age, and
incidence was reduced in children who slept under a bednet and in
children who lived in areas where the entomological inoculation
rate (EIR) was known to be low. Hazard ratios for treatment
differences adjusted for these effects were similar to unadjusted
estimates (Table 2). There was no association between iron
supplementation and malaria incidence, and there was no
evidence of interaction between treatment group and bednet
use, treatment group and EIR, and treatment group and whether
Figure 1. Trial profile.
doi:10.1371/journal.pone.0001471.g001
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shown). In a secondary analysis of all malaria episodes (with
parasites at any density), similar results were obtained (data not
shown).
Anaemia
Mean Hb concentration at the cross-sectional survey in December
was higher than in September in each of the treatment groups.
The rise was most marked in the children who were anaemic
(Hb,9 g/dL) in September and received iron supplementation.
The Hb concentration in December was slightly greater in the
3AQ+3AS and SP+3AQ groups (10.0 g/DL in each group) than
in the SP+1AS group (9.7 g/dL) (difference, adjusted for
September values, 0.33 g/dL [95%CI 0.15 to 0.50]). Three
children were severely anaemic (Hb,5 g/dL) at the time of the
December survey, one in the SP+1AS group and two in the
SP+3AS group.
Impact of intermittent treatment on the prevalence
of malaria parasitaemia and on markers of
resistance to SP
At the end of the malaria transmission season, the prevalence
of asexual stage P.falciparum parasitaemia was low in all groups
but was higher in the SP+1AS group (8.7%) than in the other
groups and was lowest in the SP+3AQ group (1.1%) (Table 3).
The prevalence of P. falciparum gametocytaemia was less than
1% in all groups. Pfdhfr mutations at positions 51, 59, 108 and a
Pfdhps mutation at position 437 were detected in almost all
parasite-positive samples at the time of the December survey
(Table 3).
Table 1. Characteristics of the study subjects at enrolment by treatment group.
..................................................................................................................................................
SP+1AS SP+3AS 3AQ+3AS SP+3AQ
N 503 504 500 513
Male (%) 47% 49% 49% 49%
Mean (range) age (months) 32 (5,60) 32 (6, 60) 32 (6, 60) 34 (6, 60)
Age
,12 months 50 (10%) 47 (9%) 58 (12%) 52 (10%)
12–23 months 130 (26%) 116 (23%) 109 (22%) 116 (23%)
24–35 months 120 (24%) 134 (27%) 109 (22%) 112 (22%)
36–47 months 106 (21%) 113 (22%) 123 (25%) 120 (23%)
48–59 months 97 (19%) 94 (19%) 101 (20%) 113 (22%)
Area
High EIR 152 (30%) 153 (30%) 151 (30%) 152 (30%)
Low EIR 351 (70%) 351 (70%) 349 (70%) 361 (70%)
Bednet use{ 17% (85/490) 21% (104/503) 17% (85/489) 17% (85/486)
Hb concentration in September (mean g/dl, range) 9.1 (3.9–13.7) 9.0 (3.4–14.0) 9.1 (4.7–13.4) 9.1 (4.2–12.8)
%H b ,9 g/dl in September 46% (230/497) 45% (220/486) 44% (218/492) 43% (215/499)
Asexual P.falciparum prevalence in September 28% (129/459) 27% (123/448) 28% (129/457) 26% (120/466)
Percent of tested samples in September positive for dhfr triple
mutation (51 59 and 108)
79% (66/85) 72% (53/74) 75% (65/86) 86% (68/79)
Percent of tested samples in September positive for dhps mutation
(437) (none with 540)
52% (51/98) 50% (50/81) 49% (42/85) 56% (40/71)
Gametocyte prevalence in September 7.2% (33/459) 7.1% (32/448) 5.9% (27/457) 7.5% (35/466)
{sleeps under an intact or impregnated net.
EIR=entomological inoculation rate
doi:10.1371/journal.pone.0001471.t001
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Table 2. Incidence of malaria by age, bednet usage, area of
residence and treatment group.
......................................................................
Cumulative
incidence*
Crude Hazard
Ratio#
Adjusted Hazard
Ratio (95%CI)
Treatment group
SP+1AS 48/503 (9.5%) 1 1
SP+3AS 44/504 (8.7%) 0.93 0.90 (0.60–1.36)
3AQ+3AS 54/500 (10.8%) 1.15 1.13 (0.76–1.67)
SP+3AQ 25/513 (4.9%) 0.51 0.50 (0.31–0.81)
Age at enrolment
,12 months 10/207 (5.0%) 1 1
1–2 yrs 24/471 (5.2%) 1.2 1.2 (0.56–2.6)
2–3 yrs 49/475 (10.5%) 2.3 2.4 (1.2–4.9)
3–4 yrs 48/462 (10.5%) 2.3 2.4 (1.2–4.9)
4–5 yrs 40/405 (10.0%) 2.3 2.4 (1.2–5.0)
Bednet use {
Yes 20/359 (5.6%) 1 1
No 148/1609 (9.3%) 1.7 1.6 (1.0–2.6)
Area
Low EIR 26/608 (4.4%) 1 1
High EIR 145/1412 (10.4%) 2.5 2.6 (1.7–4.0)
*riskdifferencescomparedtotheSP+1ASgroup are:SP+3AS,0.81%(95%CI22.7%,
+4.4%); 3AQ+3AS 21.3% (25.0%, +2.5%); and SP+3AQ 4.7% (+1.5%, +7.8%).
#based on data for 1968 individuals who were followed up and had covariate
data. Crude hazard ratios, including those with missing covariate data, were
0.92, 1.14 and 0.50 for SP+3AS, 3AQ+3AS and SP+3AQ respectively.
{defined as sleeping under an intact or impregnated net.
doi:10.1371/journal.pone.0001471.t002
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The incidence of adverse reactions was recorded during the three
days after each treatment round (Table 4). Adverse events were
more common in the SP+3AQ and 3AQ+3AS groups than in the
SP+1AS and SP+3AS groups, with fever and vomiting the most
commonly reported adverse events. No severe skin or neurological
reactions were reported. A rash was noted in 8 children; in none
was this suggestive of Stevens Johnson syndrome. Two children
were treated for severe malnutrition. Only four children died
during the period of surveillance. An 18-month old boy in the
SP+1AS group died of burns, a 2 year old girl in the 3AQ+3AS
group died of dysentery and a 12 month old girl in this group died
of a febrile illness characterized by vomiting and diarrhoea. She
was treated with both an antimalarial and an antibiotic but died
4 days after the start of treatment. The final death was that of a 5-
year old boy in the SP+3AQ who died of a febrile illness and
convulsions; his blood film was negative. The mortality rate of 2
per 1000 (4/2020) among the study children was lower than the
rate of 6 per 1000 in the same age group in the rest of the
population in the demographic surveillance area during the same
period (A Marra, personal communication).
DISCUSSION
The results of this trial are consistent with those of a previous trial
of seasonal IPT carried out in Niakhar [14] which showed a high
level of protection against clinical attacks of malaria in children
who received three courses of treatment with SP and 1AS given
during the malaria transmission season. In the current study, four
treatment regimens were investigated including the one (SP+1AS)
used in the previous trial. The SP+3AQ regimen proved to be the
most effective as judged by the incidence of clinical episodes of
malaria and by the prevalence of parasitaemia at the end of the
malaria transmission season. No placebo group was included in
the current study for ethical reasons so it is not possible to calculate
Figure 2. Kaplan Meier estimate of the cumulative incidence of malaria during the 3 months of follow-up.
doi:10.1371/journal.pone.0001471.g002
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proved to be twice as effective as the SP+1AS regimen used in the
previous study, which gave 86% protection against clinical attacks
of malaria, it could be expected to have provided 93% protection.
It has been questioned whether seasonal IPT would provide
significant added benefit to that provided by ITNs. Overall, usage
of intact untreated nets or ITNs was relatively low in the study
community (18%); use of an intact net or an ITN was associated
with a significantly reduced risk of a clinical attack of malaria.
Analysis of the interaction between net use and seasonal IPT
provided no evidence that IPT effectiveness differed between users
and non-users of bednets but the study was not designed to assess
this interaction and this requires further study.
The enhanced performance of the SP+3AQ regimen over those
containing artesunate is likely to be due to the fact that both SP
and amodiaquine have relatively long half-lives and that the
protective effect of this regimen was achieved, at least in part,
through chemoprophylaxis. This view is supported by the results
of a trial of seasonal IPT conducted in Ghana which showed that
monthly drug administration with SP+3AS was almost twice as
effective as treatment given every two months (Kweku et al.
unpublished). It seems probable that long-acting drugs will be
needed for maximal effectiveness of seasonal IPT, and inclusion of
artemisins in drug regimens for IPT is probably not useful due to
their short action. At present SP can be used in Senegal but in
other areas where there are higher levels of resistance to SP and
amodiaquine this combination may be less effective for seasonal
IPT. If long acting drugs are required for seasonal IPT, as seems to
be the case, there are only a few possible alternatives-currently
mefloquine or pyronaridine.
It is important that the need for a long-acting drug to replace SP
for prophylaxis in pregnant women and perhaps in infants and
young children, is born in mind by those involved in the
development of new anti-malarial drugs such as the Medicines
for Malaria Venture. In this study, the most effective regimen
involved a three-day course of treatment and it is uncertain how
well this would be followed outside the situation of a clinical trial.
New prophylactic drugs should ideally be effective when given as a
single treatment.
No serious adverse event attributable to study medication was
observed. Minor adverse events such as vomiting, headache and
subjective fever were significantly more frequent in children who
received amodiaquine-containing preparations than in those who
received artesunate and SP. However, overall the interventions
were well tolerated. What was recorded as vomiting may include
some children who spat out the medicine in reaction to the bitter
taste of amodiaquine. Nevertheless, adverse events should be
monitored if drugs are used on a large scale for IPT. Development
of a liquid paediatric formulation would facilitate administration of
IPT and might reduce minor adverse events and increase
compliance.
The trial used a systematic rather than random allocation, but
the method used was very unlikely to have introduced selection
bias. The trial was not blinded; this could be a factor in higher
Table 4. Adverse events recorded during the week after each treatment by treatment group.
..................................................................................................................................................
SP+1AS SP+3AS 3AQ+3AS SP+3AQ P-value*
N=504 N=501 N=495 N=509
% children (n) with any symptom (95% CI) 8.1% (41) (6.9%, 10.9%) 9.6% (48) (7.1%, 12.5%) 24% (120) (21%, 28%) 32% (164) (28%, 36%) ,0.001
convulsion 0% (0) 0.2% (1) 0% (0) 0% (0) 0.390
agitation 0.6% (3) 0.4% (2) 2.6% (13) 5.7% (29) ,0.001
headache 1.2% (6) 0.4% (2) 2.4% (12) 5.7% (29) ,0.001
fever 5.0% (25) 4.2% (21) 9.9% (49) 11.2% (57) ,0.001
vomited 1.6% (8) 1.8% (9) 6.3% (31) 11.2% (57) ,0.001
rash 0.2% (1) 0.4% (2) 0.2% (1) 0.8% (4) 0.405
dizziness 0% (0) 0% (0) 0.4% (2) 0.8% (4) 0.064
diarrhoea 2.6% (13) 2.8% (14) 5.3% (26) 4.7% (24) 0.060
Abdominal pain 0.2% (1) 0% (0) 0.8% (4) 2.0% (10) 0.001
other 1.2% (6) 2.6% (13) 12% (60) 15% (78) ,0.001
*P-value from chi-squared test of homogeneity.
The percentages of children with symptoms on at least one treatment occasion are shown.
doi:10.1371/journal.pone.0001471.t004
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Table 3. The prevalence of parasitaemia, and proportion of parasitaemic children carrying parasites positive for DHFR and DHPS
mutations associated with resistance to pyrimethamnine and suphadoxine in December, after administration of IPT during the
preceding 3 months.
..................................................................................................................................................
Asexual parasite prevalence Risk difference (95%CI) Gametocyte prevalence DHFR triple mutation DHPS 437
SP+1AS 8.7% (38/438) Reference 4/438 24/24 27/28
SP+3AS 1.8% (8/439) 6.9% (3.9%,9.8%) 0/439 4/5 3/3
3AS+3AQ 3.4% (15/441) 5.3% (2.1%, 8.4%) 1/441 9/9 6/9
SP+3AQ 1.1% (5/443) 7.5% (4.7%, 10.4%) 4/443 5/5 5/5
doi:10.1371/journal.pone.0001471.t003
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regimens, if there was a perception among parents of participants
that the yellow tablets were more likely to cause side effects.
Intermittent treatment is likely to select for resistance. In a small
study conducted in Ghana [23] this was detected after a single
treatment with SP but selection for resistant parasites was not
observed in a study of SP IPT in infants in Mozambique [24]. In
our study, few children had malaria parasitaemia at the end of the
malaria transmission season but, in those who did, nearly all
parasites carried molecular markers of resistance to pyrimeth-
amine and sulphonamides; there were no major differences
between groups. The significance of this selection is uncertain.
These parasites are likely to represent only a very small proportion
of the parasites in the study population carrying markers of
resistance to pyrimethamine (the triple DHFR mutation was
present in 78% of individuals before in the start of the trial). In
addition, very few of the children carrying resistant parasites were
gametocytaemic and likely to transmit the infection. However, if
IPT was to be used over a period of several years its impact on the
parasite population would need to be monitored carefully.
Drug costs will an important issue if seasonal IPT is
implemented widely. Amodiaquine is much cheaper than
artesunate (currently the difference in cost is about 5 fold) so the
SP+3AQ regimen has a major advantage over AS containing
regimens on these grounds as well as on those of efficacy.
This study has focused on the use of anti-malarial drugs given in
the community to prevent malaria. An alternative approach that is
now being adopted widely in some countries, such as Uganda, is
home management of febrile illnesses with anti-malarials and, as
demonstrated in Ethiopia [25] this approach can reduce mortality.
However, in areas of seasonal transmission of malaria there may be
considerable overlap between home management and intermittent
preventive treatment, unless parasitological diagnosis is performed
routinely, because of the frequency of fevers in young children
during the malaria transmission season. For example, in an area of
The Gambia adjacent to the one in which the current study was
done, home treatment for fever resulted in children aged 3 months
to 9 years receiving an average of four treatments with an anti-
malarial during the course of the malaria transmission season [26], a
similar frequency of drug administration to that employed in this
trial. Drug pressure is likely to be similar with each approach.
The results of this trial are very encouraging and show that in
Senegal SP+3AQ is a highly effective regimen for intermittent
preventive treatment. Tolerability and acceptability need to be
carefully monitored in futures studies. Regimens containing
artesunate are less effective. Thus, artesunate combinations can
be reserved for treatment of clinical cases of malaria in which the
rapid action of artemisinins is especially beneficial. In this trial,
study drugs were administered by staff supported by the research
team. Effectiveness studies are now required to identify ways in
which full participation of the community can be obtained to
achieve a high level of coverage with this intervention.
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